Prolia vs Tymlos
Side-by-side cost comparison based on Medicare Part D data
Prolia
Denosumab
Manufactured by Amgen
Tymlos
Abaloparatide
Manufactured by Radius Health
Prolia costs 66% less per claim than Tymlos ($632.00 vs $1,839.00). A generic version of Prolia is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Prolia | Tymlos |
|---|---|---|
| Avg Cost Per Claim | $632.00 | $1,839.00 |
| Total Medicare Spending | $1.6B | $456.0M |
| Total Beneficiaries | 1,240,000 | 28,000 |
| Total Claims | 2,480,000 | 248,000 |
| Annual Cost/Patient | $1,264.00 | $16,286.00 |
| Year-over-Year Change | +6.4% | +14.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Amgen | Radius Health |
| Condition | Osteoporosis | Osteoporosis |
| Generic Name | Denosumab | Abaloparatide |
Prolia vs Tymlos: What the Data Shows
Prolia (Denosumab) and Tymlos (Abaloparatide) are both used to treat osteoporosis. Based on Medicare Part D data, Prolia costs $632.00 per claim, which is 66% less than Tymlos at $1,839.00 per claim.
Medicare spent $1.6B on Prolia and $456.0M on Tymlos. In terms of patient reach, Prolia serves more beneficiaries (1,240,000 vs 28,000).
Year-over-year spending changed +6.4% for Prolia and +14.6% for Tymlos. Tymlos saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Prolia is cheaper at $632.00 per claim, compared to $1,839.00 for Tymlos. That makes Prolia about 66% less expensive per claim based on Medicare Part D data.
Yes, both Prolia and Tymlos are used to treat osteoporosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Denosumab and generic Abaloparatide can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.6B on Prolia covering 1,240,000 beneficiaries, and $456.0M on Tymlos covering 28,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.